Duloxetine Hcl
Product Images NDC 80425-0013

12 FDA label images from Advanced Rx Of Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Dulox #30 (Duloxetine HCl Dr 30mg Cap Qty 30 Ndc 80425 0013)

Dulox #30 (Duloxetine HCl Dr 30mg Cap Qty 30 Ndc 80425 0013)
Packaging label for Duloxetine HCL DR 30mg capsules, 30-count, by Advanced Rx of Tennessee, LLC. Includes NDC 80425-0013-01 with lot number 30DUL301121 and expiration date 11/30/2021. The label features storage instructions, a barcode, and a notice about federal law restricting dispensing.*
FDA Label Image

Dulox #60 (Duloxetine HCl Dr 30mg Cap Qty 60 Ndc 80425 0013)

Dulox #60 (Duloxetine HCl Dr 30mg Cap Qty 60 Ndc 80425 0013)
Label for Duloxetine HCL DR 30 mg capsules, 60 count, labeled by Advanced Rx of Tennessee, LLC, NDC 80425-0013. The label includes storage instructions, lot number 60DUL301221, expiration date 11/2022, and a logo of Advanced Rx.*
FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
A line graph comparing the proportion of patients with relapse over time (days) from randomization, showing two lines: one for placebo and one for Duloxetine. The x-axis represents time in days, and the y-axis shows the proportion of patients experiencing relapse. The placebo group shows a higher relapse proportion over time compared to the Duloxetine group.*
FDA Label Image

Fig 10 (Fig 10)

Fig 10 (Fig 10)
A line graph comparing the percentage of patients improved between placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF), ranging from >0 to 100%. The y-axis indicates the percentage of patients improved, ranging from 0 to 90%. The graph features two lines, one for placebo and one for Duloxetine, with Duloxetine showing higher patient improvement percentages across most levels of pain improvement.*
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) from randomization between two treatments: Placebo and Duloxetine. The graph shows relapse proportions increasing over approximately 250 days, with the Placebo group having a higher relapse rate than the Duloxetine group.*
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups labeled as Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo, with different lines representing each group.*
FDA Label Image

Fig 4 (Fig 4)

Fig 4 (Fig 4)
A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. It compares Duloxetine HCL DR 60 mg BID, Duloxetine 60 mg QD, and placebo groups over a range of pain improvement percentages from 0 to 100.*
FDA Label Image

Fig 5 (Fig 5)

Fig 5 (Fig 5)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows patient improvement trends across different pain improvement thresholds.*
FDA Label Image

Fig 6 (Fig 6)

Fig 6 (Fig 6)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four lines compare Duloxetine HCL DR doses of 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The y-axis represents percent of patients improved, and the x-axis shows percent improvement in pain. The graph includes a legend identifying each line by dose or placebo.*
FDA Label Image

Fig 8 (Fig 8)

Fig 8 (Fig 8)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The graph shows two plotted lines with markers for each group over a range of percent improvement values from greater than 0 to 100.*
FDA Label Image

Fig 9 (Fig 9)

Fig 9 (Fig 9)
A line graph comparing the percentage of patients improved over various levels of percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from greater than 0% to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Duloxetine shows a consistently higher percentage of patient improvement than placebo across the range.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Duloxetine hydrochloride (Duloxetine HCL DR), showing its molecular configuration with a naphthalene ring, thiophene ring, and amine group with hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.